We're taking a closer look at Cytokinetics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 4.7% compared to -0.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
-
Cytokinetics has moved 91.5% over the last year compared to 34.1% for the S&P 500 -- a difference of 57.4%
-
CYTK has an average analyst rating of buy and is -31.68% away from its mean target price of $80.65 per share
-
Its trailing 12 month earnings per share (EPS) is $-5.36
-
Cytokinetics has a trailing 12 month Price to Earnings (P/E) ratio of -10.3 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $-4.9 and its forward P/E ratio is -11.2
-
CYTK has a Price to Earnings Growth (PEG) ratio of -0.68, which shows the company is fairly valued compared to its earnings.
-
The company has a Price to Book (P/B) ratio of 59.63 in contrast to the S&P 500's average ratio of 4.74
-
Cytokinetics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
-
Cytokinetics has on average reported free cash flows of $-185955500.0 over the last four years, during which time they have grown by an an average of -33.6%